Bioengineering to combat the tuberculosis pandemic
抗击结核病流行的生物工程
基本信息
- 批准号:MR/P023754/1
- 负责人:
- 金额:$ 44.49万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2017
- 资助国家:英国
- 起止时间:2017 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Infectious diseases remain an ongoing cause of poor health and mortality in the poorest countries in the world. Tuberculosis kills more humans than any other infection and is principally a disease of poverty. Unfortunately recent studies examining new vaccine approaches or shorter antibiotic courses have not been successful, demonstrating that more research and understanding of the disease is required to combat the pandemic. Tuberculosis is also becoming progressively more resistant to antibiotics used to treat it. It is widely accepted that highly innovative approaches that draw on diverse specialists are required to achieve control of tuberculosis.This project will combine expertise at the University of Southampton, which specifically focuses on cross-disciplinary research, with the African Health Research Institute in Durban, a state-of-the-art laboratory set up to be at the heart of the tuberculosis and HIV pandemics. It is centred on a new way of studying infection in the laboratory, which relies on an innovative cellular spraying technique that permits studies of infected human cells in three-dimensions and attached to lung supporting fibres. This system has been developed at Southampton and will be introduced laboratories in Durban, where we will harness the expertise in investigation of samples from patients and fluidics to further develop the model. We will prove that this system can be used to understand how infection occurs, to investigate new vaccine strategies and to identify novel antibiotic regimes.There will be four programmes of work which will take place both in Southampton and Durban, with regular exchange of researchers between the centres, joint conferences and scheduled videoconferences. First, we will study cells isolated from lungs removed during surgery as part of their routine clinical care. We will compare cells from patients who either are controlling tuberculosis infection or who have developed disease to examine the factors leading to active disease. Secondly, we will separate cells which are controlling infection from cells where infection is progressing and systematically study biology to understand how human cells either control infection or permit progression. Thirdly, we will change the host immune cells using genetic engineering technology to unpick which components of the body's immune response is beneficial in controlling infection compared to that which causes damage. Finally, we will combine the human cell system with miniature fluid irrigation apparatus to permit modulation of antibiotic concentrations over time to identify l more effective treatment regimes.This project will deliver a transformative approach to the tuberculosis pandemic, identifying new vaccine targets and antibiotic regimes, and initiate a highly complimentary collaboration which we will develop over the two years to deliver innovative cross-disciplinary research to address diseases affecting the poorest in the world.
传染病仍然是世界上最贫穷国家健康状况不佳和死亡率高的一个持续原因。结核病比任何其他传染病造成的死亡人数都多,它主要是一种贫困疾病。不幸的是,最近研究新的疫苗方法或更短的抗生素疗程的研究并不成功,这表明需要对这种疾病进行更多的研究和了解,以对抗这种流行病。结核病对用来治疗结核病的抗生素的抗药性也越来越强,人们普遍认为,要实现结核病的控制,就必须采用高度创新的方法,吸收不同的专家,该项目将把南安普顿大学专门侧重于跨学科研究的专门知识与德班的非洲卫生研究所结合起来,这是一个最先进的实验室,位于结核病和艾滋病流行病的中心。它的核心是在实验室中研究感染的新方法,该方法依赖于一种创新的细胞喷雾技术,该技术允许在三维空间中研究受感染的人体细胞并附着在肺部支持纤维上。该系统已在南安普顿开发,并将引入德班的实验室,在那里我们将利用患者样本调查和射流技术的专业知识进一步开发该模型。我们将证明,这一系统可用于了解感染是如何发生的,调查新的疫苗战略和确定新的抗生素方案。将有四个工作方案将在南安普顿和德班进行,各中心之间定期交换研究人员,举行联合会议和预定的电视会议。首先,我们将研究从手术中取出的肺中分离的细胞,作为其常规临床护理的一部分。我们将比较来自正在控制结核感染或已发生疾病的患者的细胞,以检查导致活动性疾病的因素。其次,我们将把控制感染的细胞与感染进展的细胞分开,并系统地研究生物学,以了解人类细胞如何控制感染或允许感染进展。第三,我们将利用基因工程技术改变宿主的免疫细胞,以挑选出与造成损害的免疫反应相比,身体免疫反应中哪些成分有利于控制感染。最后,我们将联合收割机与微型流体冲洗装置相结合,以允许随着时间的推移调节抗生素浓度,从而确定更有效的治疗方案。该项目将为结核病大流行提供一种变革性方法,确定新的疫苗靶点和抗生素方案,并启动一个高度互补的合作,我们将在两年内发展,以提供创新的跨-学科研究,以解决影响世界上最贫穷者的疾病。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
WITHDRAWN: Personal respirators for population level control of the COVID19 pandemic.
撤回:用于人口层面控制新冠病毒大流行的个人呼吸器。
- DOI:10.1016/j.jinf.2020.04.044
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Elkington P
- 通讯作者:Elkington P
Understanding the tuberculosis granuloma: the matrix revolutions.
- DOI:10.1016/j.molmed.2021.11.004
- 发表时间:2022-03
- 期刊:
- 影响因子:13.6
- 作者:Elkington P;Polak ME;Reichmann MT;Leslie A
- 通讯作者:Leslie A
A Personal Respirator to Improve Protection for Healthcare Workers Treating COVID-19 (PeRSo).
- DOI:10.3389/fmedt.2021.664259
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Elkington PT;Dickinson AS;Mavrogordato MN;Spencer DC;Gillams RJ;De Grazia A;Rosini S;Garay-Baquero DJ;Diment LE;Mahobia N;Mant A;Baynham T;Morgan H
- 通讯作者:Morgan H
Personal respirators for population level control of the COVID19 pandemic.
用于控制 COVID19 大流行的人口水平的个人呼吸器。
- DOI:10.1016/j.jinf.2020.04.025
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Elkington P
- 通讯作者:Elkington P
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul Elkington其他文献
Managing project risks: a case study from the utilities sector
管理项目风险:公用事业部门的案例研究
- DOI:
10.1016/s0263-7863(00)00034-x - 发表时间:
2002 - 期刊:
- 影响因子:8
- 作者:
Paul Elkington;C. Smallman - 通讯作者:
C. Smallman
Matrix metalloproteinase expression by Mycobacterium tuberculosis-infected human macrophages is modulated by interferon-gamma and interleukin-4
- DOI:
10.1016/j.jinf.2010.09.010 - 发表时间:
2010-12-01 - 期刊:
- 影响因子:
- 作者:
Rachel Moores;Lucinda Rand;Paul Elkington;Jonathan Friedland - 通讯作者:
Jonathan Friedland
An investigation into the factors driving tissue destruction in central nervous tuberculosis by investigating a cellular model and the immunopathology in patients
- DOI:
10.1016/j.jinf.2008.01.022 - 发表时间:
2008-04-01 - 期刊:
- 影响因子:
- 作者:
Justin Green;Guy Thwaites;Hong Chau Tran;Anwen Bullen;Paul Elkington;Dan Agranoff;Jeremy Farrar;Jon Friedland - 通讯作者:
Jon Friedland
Modulation of metalloproteinase activity in tuberculosis by Interleukin-17 and anti-tuberculous drugs
- DOI:
10.1016/j.jinf.2009.10.023 - 发表时间:
2009-12-01 - 期刊:
- 影响因子:
- 作者:
Shivani Singh;Paul Elkington;Harriet Gardiner;Luisa Saraiva;Jonathan Friedland - 通讯作者:
Jonathan Friedland
Paul Elkington的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul Elkington', 18)}}的其他基金
Investigating local determinants of outcome in human tuberculosis
研究人类结核病结果的局部决定因素
- 批准号:
MR/W025728/1 - 财政年份:2022
- 资助金额:
$ 44.49万 - 项目类别:
Research Grant
Investigating multi-drug resistant tuberculosis in the 3-dimensional bioelectrospray cell culture model
在三维生物电喷雾细胞培养模型中研究多重耐药结核病
- 批准号:
MR/N006631/1 - 财政年份:2015
- 资助金额:
$ 44.49万 - 项目类别:
Research Grant
相似海外基金
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis
噻唑啉-吡啶酮化合物作为结核病新药
- 批准号:
10698829 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别:
Nitrosative stress and NO detoxifying reaction mechanisms in microbial nonheme diiron proteins
微生物非血红素二铁蛋白的亚硝化应激和NO解毒反应机制
- 批准号:
10656107 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别:
Structural characterization of MCE transport systems from Mycobacterium tuberculosis
结核分枝杆菌 MCE 转运系统的结构表征
- 批准号:
10681871 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别:
Oklahoma Center for Respiratory and Infectious Diseases
俄克拉荷马州呼吸和传染病中心
- 批准号:
10628212 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别:
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM
UM-1098 的开发:一种新型合成 TH17 诱导佐剂和递送系统
- 批准号:
10935819 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别:
Novel gyrase inhibitors targeting Mycobacterium tuberculosis
针对结核分枝杆菌的新型旋转酶抑制剂
- 批准号:
10725711 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别:
Development of a Dual-Targeting ClpP Activating Antibiotic
双靶点 ClpP 激活抗生素的开发
- 批准号:
10760586 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别:
Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis
诱导支气管相关淋巴组织在潜伏性结核病中的作用
- 批准号:
10764569 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别:
The Impact of the Cystic Fibrosis infection environment on biofilm development of nontuberculous mycobacteria
囊性纤维化感染环境对非结核分枝杆菌生物膜发育的影响
- 批准号:
10657135 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别:
Research Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State University
科罗拉多州立大学落基山区域生物防护实验室的研究资源和劳动力发展
- 批准号:
10793907 - 财政年份:2023
- 资助金额:
$ 44.49万 - 项目类别: